Early in 2018, SCU received approval from Australia ASX regulator to venture into the cannabis cosmetic beauty product’s research and development. This allows SCU to carry out cannabis stem cell genetics, research and development of cannabis seed breeding as well as its medical applications of cannabinoid (CBD) and derivatives and other active compounds in cannabis plant.
In 2018, SCU has also successfully patented and completed the research and development of Dendrobium stem cell product in 2017 and started pilot production and marketing in Asia.
In 2016, SCU successfully commercialised the processing and production of pharmaceutical grade Resina Draconis medicine and has been a major supplier to China and Asia markets since.
Entry barriers are high for stem cell bio-technology businesses because the inventors take many years or even an entire lifetime to conduct research and development of a successful product for commercial use.
SCU uses patents and trademarks to protect our investment in proprietary formulation.
SCU has applied for international patent protection (PCT/SG2014/000515) for its proprietary technology and method of isolating meristematic plant stem cells. It has also filed individual patent applications in China (201410486185.1) and Taiwan (104103026).
Patent Number - PCT/SG2014/000515
Patent Number - 201410486185.1
Patent Number - 104103026